Search and filter stories that passed editorial review. Evidence strength, regulatory status, and guideline position are shown separately and are never inferred from one another.
In the randomized, open-label, phase 3 DeLLphi-304 trial, tarlatamab significantly extended overall survival compared with chemotherapy in patients with extensive-stage small cell lung cancer that had progressed after platinum-based chemotherapy…
In the randomized, placebo-controlled ADRIATIC trial, durvalumab given as consolidation therapy after concurrent chemoradiotherapy meaningfully extended both overall survival and progression-free survival compared with placebo in limited-stage small cell lung…